-

Xlear Submits COVID-19 Pre-Emergency Use Authorization Request with FDA Regarding Use of Xlear Nasal Spray to Help in Combating SARS-CoV-2

WASHINGTON--(BUSINESS WIRE)--Today, Xlear is filing a Pre-Emergency Use Authorization (Pre-EUA) Request with the U.S. Food and Drug Administration (FDA). The Pre-EUA is a first step in seeking authorization of Xlear Nasal Spray as a new hygiene tool to help in combat the SARS-CoV-2 virus, the virus that causes COVID-19.

Xlear’s Pre-EUA Request is based on initial data suggesting Xlear Nasal Spray may reduce SARS-CoV-2 viral load in the nose, and otherwise attenuate the virus. “Studies show that regular nasal cleansing may help reduce viral infections, including from the SARS-CoV-2 virus (COVID-19),” said Dr. Gustavo Ferrer, a doctor and global respiratory disease expert who has studied the use of Xlear Nasal Spray to combat SARS-CoV-2. “The concept is straight-forward: Cleansing the nose means less virus, less virus produces less risk of infection,” Dr. Ferrer added.

The Pre-EUA Request is focused on the cleansing uses of Xlear, however it follows on recent studies suggesting Xlear is both antiviral and virucidal against SARS-CoV-2:

The linchpin of FDA’s COVID-19 EUA determinations is a risk-benefit assessment — given the threat of a global pandemic, do the possible benefits of the emergency use, outweigh any known risks. Xlear has been used by millions of people over the last twenty years for cleansing and moisturizing the nasal cavities without a single report of a significant adverse event. At the same time, preliminary data shows Xlear has potential benefits versus SARS-CoV-2. “More research will be needed to confirm the effectiveness of Xlear versus SARS-CoV-2. However, we believe the available data clearly shows potential benefits outweigh any practically non-existent risks, ” said Nate Jones, CEO of Xlear. “We hope to move forward quickly with FDA to address a gap in current hygiene strategies against SARS-CoV-2. People should be using Xlear as part of a layered defense to prevent getting COVID-19. If everyone used Xlear, in addition to taking other steps recommended by public health officials, we believe we could drive SARS-CoV-2 infection rates down nationwide,” Jones added.

Xlear is currently sold in over 50,000 pharmacies, grocery stores, and online as a nasal irrigant for cleansing and moisturizing the nasal cavities.

More information on Xlear: https://xlear.com/

Contacts

Jeff Gulko
617.304.7339
jeff@thegulkogroup.com

More News From Xlear

Xlear Sues FTC for Unlawful Scientific Censorship

SALT LAKE CITY--(BUSINESS WIRE)--Xlear Sues FTC for Unlawful Scientific Censorship; FTC’s marketing substantiation rules violate Supreme Court Loper Ruling...

Xlear, Inc. Commends Utah for its Leadership Role in Being the First State in the Nation to Ban Fluoride from its Public Drinking Water

AMERICAN FORK, Utah--(BUSINESS WIRE)--Nathan Jones, CEO of Xlear, Inc. a Utah-based leading natural health products company, issues the following statement. “As CEO of Xlear, Inc., and a keen proponent of eliminating fluoride from public drinking water, I congratulate Utah’s historic decision to become the first state to ban the addition of fluoride to its public and residential water systems. "The passing of HB0081 by the Utah legislature represents a pivotal moment for health freedom and indi...

DOJ Asks Court to Dismiss FTC-Xlear Lawsuit

AMERICAN FORK, Utah--(BUSINESS WIRE)--DOJ ASKS COURT TO DISMISS FTC-XLEAR LAWSUIT; Calls into Question FTC’s Authority to Require Clinical Studies for Non-Pharmaceutical Health Products...
Back to Newsroom